A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
- Gennari A Division of Medical Oncology, E.O. Ospedali Galliera, Genova, Italy. Electronic address: alessandra.gennari@galliera.it.
- Sun Z IBCSG Statistical Center, Boston, USA; Frontier Science and Technology Research Foundation, Boston, USA.
- Hasler-Strub U Breast Center, Kantonsspital St. Gallen, St. Gallen; SAKK, Bern, Switzerland.
- Colleoni M Division of Medical Senology, European Institute of Oncology, Milan, Italy.
- Kennedy MJ Department of Medical Oncology, St. James Hospital, Dublin, Ireland.
- Von Moos R FMH Medical Oncology, Chur, Switzerland.
- Cortés J Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Department of Medical Oncology, Ramon y Cajal University Hospital, Barcelona, Spain.
- Vidal MJ Breast Cancer & Melanoma Group, Hospital Universitari Vall D'Hebron, Barcelona, Spain.
- Hennessy B Centre for Systems Medicine, Beaumont Hospital, Dublin, Ireland.
- Walshe J Clinical Trials, Ireland.
- Parraga KA Oncology Research Group, Hospital Universitari Sant Joan De Reus, Tarragona, Spain.
- Ribi K IBCSG Coordinating Center, Bern, Switzerland.
- Bernhard J IBCSG Coordinating Center, Bern, Switzerland; Bern University Hospital, Inselspital, Bern, Switzerland.
- Murillo SM Medical Oncology, Hospital Universitari Arnau De Vilanova De Lleida, Lleida, Spain.
- Pagani O SAKK, Bern, Switzerland; Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
- Barbeaux A Onco-Hematology, CHPLT Verviers, Verviers, Belgium.
- Borstnar S Institute of Oncology, Ljubljana, Slovenia.
- Rabaglio-Poretti M IBCSG Coordinating Center, Bern, Switzerland; Bern University Hospital, Inselspital, Bern, Switzerland.
- Maibach R IBCSG Coordinating Center, Bern, Switzerland.
- Regan MM IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Harvard Medical School, Boston, USA.
- Jerusalem G Medical Oncology, CHU Sart Tilman, Liege, Belgium.
- 2017-12-12
Published in:
- Annals of oncology : official journal of the European Society for Medical Oncology. - 2018
Adult
Aged
Aged, 80 and over
Albumins
Antineoplastic Agents
Breast Neoplasms
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Maintenance Chemotherapy
Middle Aged
Paclitaxel
Progression-Free Survival
Treatment Outcome
English
Background
The phase II SNAP trial was designed to evaluate the efficacy of alternative chemotherapy schedules for prolonged administration in HER2-negative metastatic breast cancer (MBC), after a short induction at conventional doses.
Patients and methods
Between April 2013 and August 2015, 258 women untreated with chemotherapy for MBC were randomly assigned to receive three different maintenance chemotherapy schedules after three cycles of identical induction chemotherapy: arm A, nab-paclitaxel 150 mg/m2 days 1 and 15 Q28; arm B, nab-paclitaxel 100 mg/m2 days 1, 8 and 15 Q28; arm C, nab-paclitaxel 75 mg/m2 days 1, 8, 15 and 22 Q28. Induction was three cycles nab-paclitaxel 150/125 mg/m2, days 1, 8 and 15 Q28. The primary objective was to evaluate the efficacy of each maintenance schedule, in terms of progression-free survival (PFS), as compared with the historical reference of 7-month median PFS reported by previous studies with first-line docetaxel. One-sample, one-sided log-rank tests were utilized. Quality-of-life (QoL) evaluation was carried out, and the global indicator for physical well-being was defined as the primary QoL end point; completion rates of QoL forms were >90%.
Results
In total, 255 patients were assessable for the primary end point. After 18.2-month median follow-up, 182 PFS events were observed. Median PFS was 7.9 months [90% confidence interval CI 6.8-8.4] in arm A, 9.0 months (90% CI 8.1-10.9) in arm B and 8.5 months (90% CI 6.7-9.5) in arm C. PFS in arm B was significantly longer than the historical reference of first-line docetaxel (P = 0.03). Grade ≥2 sensory neuropathy was reported in 37.9%, 36.1% and 31.2% of the patients in arm A, B and C, respectively (Grade ≥3 in 9.1%, 5.6% and 6.6% of the patients, respectively). Noteworthy, the QoL scores for sensory neuropathy did not worsen with prolonged nab-paclitaxel administration in any of the maintenance arms.
Conclusion
The SNAP trial demonstrated that alternative nab-paclitaxel maintenance schedules with reduced dosages after a short induction at conventional doses are feasible and active in the first-line treatment of MBC. Registration: ClinicalTrials.gov NCT01746225.
The phase II SNAP trial was designed to evaluate the efficacy of alternative chemotherapy schedules for prolonged administration in HER2-negative metastatic breast cancer (MBC), after a short induction at conventional doses.
Patients and methods
Between April 2013 and August 2015, 258 women untreated with chemotherapy for MBC were randomly assigned to receive three different maintenance chemotherapy schedules after three cycles of identical induction chemotherapy: arm A, nab-paclitaxel 150 mg/m2 days 1 and 15 Q28; arm B, nab-paclitaxel 100 mg/m2 days 1, 8 and 15 Q28; arm C, nab-paclitaxel 75 mg/m2 days 1, 8, 15 and 22 Q28. Induction was three cycles nab-paclitaxel 150/125 mg/m2, days 1, 8 and 15 Q28. The primary objective was to evaluate the efficacy of each maintenance schedule, in terms of progression-free survival (PFS), as compared with the historical reference of 7-month median PFS reported by previous studies with first-line docetaxel. One-sample, one-sided log-rank tests were utilized. Quality-of-life (QoL) evaluation was carried out, and the global indicator for physical well-being was defined as the primary QoL end point; completion rates of QoL forms were >90%.
Results
In total, 255 patients were assessable for the primary end point. After 18.2-month median follow-up, 182 PFS events were observed. Median PFS was 7.9 months [90% confidence interval CI 6.8-8.4] in arm A, 9.0 months (90% CI 8.1-10.9) in arm B and 8.5 months (90% CI 6.7-9.5) in arm C. PFS in arm B was significantly longer than the historical reference of first-line docetaxel (P = 0.03). Grade ≥2 sensory neuropathy was reported in 37.9%, 36.1% and 31.2% of the patients in arm A, B and C, respectively (Grade ≥3 in 9.1%, 5.6% and 6.6% of the patients, respectively). Noteworthy, the QoL scores for sensory neuropathy did not worsen with prolonged nab-paclitaxel administration in any of the maintenance arms.
Conclusion
The SNAP trial demonstrated that alternative nab-paclitaxel maintenance schedules with reduced dosages after a short induction at conventional doses are feasible and active in the first-line treatment of MBC. Registration: ClinicalTrials.gov NCT01746225.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1093/annonc/mdx772
- PMID 29228091
- Persistent URL
- https://sonar.ch/global/documents/45261
Statistics
Document views: 17
File downloads:
- fulltext.pdf: 0